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in human breast cancer
M. Thomas', M, Noguchi1 2, L. Fonseca', H. Kitagawal, K. Kinoshita' & I. Miyazaki'
'Department ofSurgery (II) and 'Operation Center, Kanazawa University Hospital, Takara-machi 13-1, Kanazawa, 920, Japan.
Summary We investigated the prognostic significance of Helix pomatia lectin (HPA) staining on disease-free
and overall survival in 120 primary breast carcinomas. HPA staining was present in 58 (48%) of these
carcinomas. It was significantly associated with axillary lymph node metastases (P<0.001) and c-erbB-2
expression (P<0.01). A univariate study revealed that disease-free and overall survival were significantly
correlated with clinical stage, tumour size, axillary lymph node metastases. HPA staining and c-erbB-2
expression. In a multivariate study, all previous prognostic indicators except HPA staining and c-erbB-2
expression were independent factors. However, stratifying the patients on the basis of HPA and c-erbB-2
status suggested that HPA+/c-erbB-2+ status was predictive of a higher incidence of axillary lymph node
metastases (P = 0.000001) and a poorer overall (P<0.0002) and a shorter disease-free (P<0.000006) survival
when compared with the other subgroups, although this combination did not provide any additional progostic
information for overall (P = 0.3544) or disease-free (P = 0.7152) survival by a multivariate analysis. For
patients in whom axillary lymph node dissection has not been performed, therefore, HPA and c-erbB-2 status
seems to be a powerful tool to discriminate subpopulations with a high recurrence risk and shorter survival
who should undergo more aggressive therapy.
The prognosis of patients with operable breast cancer is
extremely variable. Recently, tremendous efforts have been
made to assess the prognosis. The status of the axillary
lymph nodes (AX) has been shown to be closely correlated
with the prognosis (Haybittle et al., 1982). Despite the pro-
ven prognostic value of nodal status, however, some centres
have reduced the extent of AX dissection to avoid the related
morbidity such as arm oedema. Therefore, there is a clear
need to have accurate prognostic indices which do not
involve axillary surgery.
In animal models, the ability of a tumour to metastasise
may be determined through the selection of metastatic cell
populations in which alterations in cell surface carbohydrates
have been found to significantly alter the metastatic
behaviour of the tumours (Altevogt et al., 1983; Steck &
Nicolson, 1983). Currently, such differences have been
detected by means of lectins, which are sugar-binding pro-
teins and glycoproteins of non-immune origin (Goldstein et
al., 1980; Leathem et al., 1984; 1985) have described a Helix
pomatia lectin (HPA) isolated from the albumin gland of the
Roman snail, which recognises N-acetyl-galactosaminyl
residues. It apparently binds to a population of breast cancer
cells which have a higher frequency of metastases to the
regional lymph nodes. Expression of HPA binding site in
breast cancer tissue may reflect the ability of a tumour to
invade and metastasise (Fiezy, 1981; Furmanski et al.,
1981).
The c-erbB-2 oncogene encodes a 185-kDa transmembrane
receptor-like phosphoglycoprotein with tyrosine kinase
activity (Coussens et al., 1985; Akiyama et al., 1986) that is
closely related in structure, but is biologically distinct from,
the epidermal growth factor receptor (EGFR, c-erbB-1)
(Semba et al., 1985; Yamamato et al., 1986). It has been
suggested that c-erbB-2 overexpression may play a significant
role in the pathogenesis of breast disease (Berger et al., 1988).
The oncogene is amplified and overexpressed in about 15 to
30% of breast carcinomas (Slamon et al., 1989; Paik et al.,
1990; Borg et al., 1991). Several investigators have reported
an association between c-erbB-2 activation and early disease
recurrence or short survival, particularly in patients with
AX-positive disease (Slamon et al., 1989; Wright et al., 1989;
Borg et al., 1991), whereas others have reported that c-erbB-2
has limited, if any. prognostic value (Van de Vijver et al.,
1988; Thor et al., 1989).
First in this study, we investigated the prognostic value of
the HPA staining on disease-free and overall survival by
univariate and multivariate analyses. Second, we attempted
to assess whether HPA staining identified subsets of patients
with a poorer prognosis when stratified on the basis of their
c-erbB-2 status. Finally, we used multivariate analysis to
ascertain whether the presence or absence of HPA staining
contributed any additional prognostic information as a com-
bined variable with c-erbB-2 status, to disease-free and
overall survival models.
Materials and methods
Patients and treatments
One hundred and twenty paraffin blocks with tumour sam-
ples were available from patients with resectable breast
cancer treated at the Department of Surgery II, Kanazawa
University Hospital between 1978 and 1989. We selected only
patients with histologically proven invasive breast carcinomas
in whom AX dissection had been performed and had all
resected material studied histologically. A variety of mastec-
tomies was performed on all the patients. The resected
breasts, pectoralis muscles, and the dissected axillary nodes
were fixed in 10% formalin. Post-operatively, all patients
underwent various adjuvant chemoendocrine therapies. They
were followed until their death or through March, 1992.
The patients were classified according to the following
clinico-pathological and biological variables: age (<35 years
in eight, 36-50 years in 61, > 51 years in 51), menopausal
status (premenopausal in 61. postmenopausal in 59), clinical
stage (stage 1 in 24, stage 2 in 69, stage 3 in 27), tumour size
(<2.0cm in 44, 2.1-5,0 cm in 61, > 5.1 cm in 15), histologic
type (invasive duct carcinoma in 112, special type of invasive
carcinoma in eight according to The Histological
Classification of Breast Cancer by the Japan Breast Cancer
Society (1988) and the modified Histological Typing of the
WHO (1982), degree of histological AX metastases (O in 66,
1-3 in 26, >3 in 28), HPA binding (negative in 62, positive
in 58) and c-erbB-2 expression (negative in 84, positive in
36).
HPA staining method
The method used for preparation of the paraffin sections for
HPA staining was similar to that of Fukutomi et al. (1989).
Each section (5 tm-thick) was deparaffinised in xylene and
subsequently rehydrated in ethanol and finally in water.
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Endogenous peroxidase was blocked by immersion in
methanol containing 1% hydrogen peroxide (15min). After
being washed in distilled water (5 min) and in phosphate
buffered saline (PBS: pH 7.6) buffer (20 min), the sections
were incubated with 10% normal porcine serum in PBS to
reduce non-specific binding (30 min). They were then
incubated overnight at room temperature with 5 fig ml-'
diluted biotin-labelled HPA (Sigma, St Louis, MO, USA) in
PBS buffer. Sections were washed three times for 5 min with
PBS buffer between incubations. A final washing was fol-
lowed by staining with a Vectastain ABC (Avidin-
biotin-peroxidase complex) kit (Vector Laboratories Inc.
Burlingame, CA, USA) (30 min). Peroxidase activity was
visualised with 3.3'diaminobenzidine (DAB) and 1% hy-
drogen peroxide in PBS buffer (5 min). Sections were
counterstained with 0.3% methyl green, dehydrated in
ethanol cleared in xylene and mounted in malinol (Muto
Pure Chemicals, Tokyo, Japan) medium. In negative control
preparations the lectin was omitted. Most cases were clearly
either intensely positive or completely negative. In a few
cases we used the scoring described by Brooks et al. (1991).
Finally, cases were classified as positively stained (HPA+) or
negatively stained (HPA-).
Immunohistochemical staining ofc-erbB-2 oncoprotein
The expression of c-erbB-2 oncoprotein was demonstrated in
5 ,Lm sections, using a polyclonal antibody raised in rabbits
against a synthetic peptide (21 N) representing residues 1243
to 1255 of the predicted oncoprotein sequence (Gullick et al.,
1987). The detailed procedure has been described elsewhere
(Noguchi et al., 1992). The tumours were scored by assessing
the staining site (membrane and/or cytoplasm), the propor-
tion of stained cells (0%, 1% to 49%, and 50% to 100%),
and the intensity of staining (weak, +; strong, + +). If 50%
or more of the tumour cells showed intense membrane stain-
ing, they were considered to be positive (c-erbB-2+). All
other cells with less intense membrane staining or more focal
staining were considered to be negative (c-erbB-2-).
Statistical analysis
The HPA binding and other variables were analysed using
the Chi-squared test for significant association. Follow-up
data were available for the disease-free survival and the
overall survival. Disease-free and overall survival were cal-
culated as the interval from the date of the operation to the
recurrence or the death of the patient from breast cancer-
related causes, respectively. For univariate analysis, the
overall and disease-free survival were studied by the Kap-
lan-Meier method, and the log-rank test was used to analyse
differences for significance. For multivariate analysis, Cox's
life table regression model (proportional hazards general
linear model) was used to examine several parameters
simultaneously to test for their prognostic independence.
Differences were considered significant when P was less
than 0.05.
Results
Relationship ofHPA staining with other prognostic variables
Among the 120 cases studied, 62 (52%) had negative staining
and 58 (48%) had positive staining. HPA staining was
significantly associated with AX metastases (P<0.001) and
c-erbB-2 expression (P<0.01), whereas it was not
significantly associated with age, menopausal status, clinical
stage, tumour size, and histologic type (Table I).
Univariate and multivariate analyses on overall and
disease-free survival
When all the prognostic variables were examined individually
with regard to overall and disease-free survival in the
univariate model, there was a significantly increased risk of
mortality and recurrence from breast cancer in the patients
stratified by clinical stage (P<0.01), tumour size (P<0.01),
AX metastases (P<0.001), HPA staining (P<0.01) and c-
erbB-2 expression (P<0.01) (Table II). Life table analysis
demonstrated an increased risk of earlier recurrence
(P <0.002, Figure la) and shorter overall survival
(P<0.005, Figure lb) for the HPA+ group. The 10 year
disease-free survival rate after surgery was 87% in the
HPA- group and 60% in the HPA+ group. The survival
curves for both groups displayed the same tendency (87% for
the HPA - group and 63% for the HPA+ group). When all
variables were considered simultaneously in the multivariate
model to identify which variables conveyed unique prognos-
tic information, the results indicated that all previous prog-
nostic factors except HPA staining and c-erbB-2 expression
were independent indicators for increased risk of mortality
and recurrence (Table II).
Relationship between axillary lymph node metastases and HPA
and c-erbB-2 status
We compared the presence of AX metastases with both HPA
and c-erbB-2 status. Patients were categorised on the basis of
HPA and c-erbB-2 status: (a) HPA - and c-erbB2 -; (b)
HPA - and c-erbB2+; (c) HPA+ and c-erbB2 -; (d)
HPA+ and c-erbB2+. Their relationship with AX metas-
tases was highly significant (P = 0.000001, Table III). The
synchronous expression of HPA lectin and c-erbB-2 oncop-
rotein was more frequent in the group with a higher
incidence of histological AX metastases (54%). Moreover, if
we compared the patients grouped according to their HPA
status, the overexpression of the c-erbB-2 oncoprotein
Table I Correlation of HPA staining with other prognostic factors in breast cancer (n = 120)
HPA HPA
Variables positivity P-value Variables positivity P-values
Age Tumor size
< 35 yrs 22% (2/9) < 2.0cm 52% (23/44)
36-50 yrs 46% (28/60) NS 2.1-5.0 cm 49% (30/61) NS
> 51 yrs 55% (28/51) > 5.1 cm 33% (5/15)
Menopausal status Degree of AX metastases
Pre 40% (26/64) NS 0 30% (20/66)
Post 57% (32/56) 1-3 54% (14/26) P<0.001
Clinical stage >3 86% (24/28)
Stage 1 46% (11/24) c-erbB-2 expression
Stage 2 54% (37/69) NS c-erbB-2 (-) 39% (33/84) P<0.01
Stage 3 37% (10/27) c-erbB-2 (+) 69% (25/36)
Histologic type
Invasive ductal ca. 50% (56/112)
Special type of 25% (2/8) NS
invasive ca.
AX: Axillary lymph nodes.HPA AND c-erbB-2 IN BREAST CANCER
Table II Univariate and Multivariate analysis of HPA staining and other prognostic
factors on overall and disease-free survival (n = 120)
Overall survival Disease-free survival
Univariate Multivariate Univariate Multivariate
Age NS NS NS NS
Menopausal NS NS NS NS
Clinical stage <0.01 <0.01 <0.01 <0.01
Histologic type NS NS NS NS
Tumour size <0.01 <0.05 <0.01 <0.05
AX metastases <0.001 <0.01 <0.001 <0.01
HPA staining <0.01 NS <0.01 NS
c-erbB-2 expression <0.01 NS <0.01 NS
AX: Axillary lymph nodes; NS: not significant.
Table III Axillary lymph node involvement related with HPA staining and c-erbB-2 expression
Axa HPA(-)c-erbB-2(-) HPA(-)c-erbB-2(+) HPA(+)c-erbB-2(-) HPA(+)c-erbB-2(+) Total
0 62% (41) 8% (5) 24% (16) 6% (4) 100% (66)
1-3 31% (8) 15% (4) 31% (8) 23% (6) 100% (26)
> 3 7% (2) 7% (2) 32% (9) 54% (15) 100% (28)b
Total 42% (51) 9% (11) 28% (33) 21% (25) 100% (120)
aAxillary lymph node metastases: bp<0.000001.
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Figure 1 Actuarial survival curves for disease-free survival (a) and overall survival (b) for patients presenting with HPA positive or
HPA negative staining primary breast carcinomas.
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Figure 2 Actuarial survival curves for disease-free survival (a)
and overall survival (b) in the HPA/c-erbB-2 subgroups of
patients with primary breast carcinomas.
identified a subset of patients with an increase incidence of
AX metastases (P<0.05 for the HPA- group and P<0.02
for the HPA+ group, data not shown).
Prognostic significance ofHPA/c-erbB-2 status
When patients were divided into the previous four groups (a
to d), there was a significant trend for poorer overall survival
(P<0.0002) and disease-free survival (P<0.000006) with
HPA binding and c-erbB-2 overexpression (Figures 2a and
b). The prognosis for Group (a) was significantly better than
that for the other three groups (Figures 3a and b). The mean
10 year disease-free survival rate was 93% for Group (a)
compared with 60, 80 and 39% for Groups (b), (c) and (d),
respectively, whereas the mean 10 year overall survival rate
was 93% for Group (a), 69% for Group (b), 79% for Group
(c) and 46% for Group (d). Of the four survival and disease-
free survival distributions, patients who were HPA+ and
c-erbB2 + had a significantly worse disease outcome
(P<0.000006, 10 year disease-free rate of 39%, Figure 2a)
and shorter survival (P<0.0002, 10 year survival of 46%,
Figure 2b) compared with the other groups; this suggests that
HPA staining and c-erbB-2 expression are additive as prog-
nostic indicators and may predict for a worse prognosis when
both are positive. When the c-erbB-2 expression are additive
as prognostic indicators and may predict for a worse prog-
nosis when both are positive. When the c-erbB-2 oncoprotein
is overexpressed, a subset of patients is defined among the
HPA- group which had a shorter survival and earlier recur-
rence compared to the HPA+/c-erbB2 group (Figures 2a and
b). No attempt was made to determine whether the combina-
tion of HPA staining and c-erbB-2 expression can identify
group at higher recurrence risk in both AX-positive and
AX-negative groups, because the number of cases was too
small in this series.
01 To investigate whether the combination of HPA staining
and c-erbB-2 oncoprotein expression gives any additional
prognostic information for these patients, a multivariate
1 analysis was conducted including all the prognostic factors
selected in this study with the addition of the combination
between HPA and c-erbB-2 status. However, this combina-
tion did not provide any additional prognostic information
for overall (P= 0.3544) or disease-free (P= 0.7152) sur-
vival.
Discussion
Our data and those from other laboratories (Leathem &
Brooks, 1987; Fenlon et al., 1987; Fukutomi et al., 1989;
Brooks & Leathem, 1991) indicate that HPA staining may be
a valuable prognostic indicator in patients with primary
breast cancer and may identify subsets of patients in defined
prognostic groupings who have a worse prognosis. With
regard to various clinicopathologic features, however, HPA
staining has been associated with endocrine receptor status
(Klein et al., 1981; Fukutomi et al., 1989), tumour stage
(Leathem et al., 1985) and high nuclear grade (Fukutomi et
al., 1989), implying an association between the HPA staining
and enhanced malignancy of the tumour cells. The relation-
ship between HPA binding and lymph node metastases is
controversial, however it has been reported that HPA stain-
ing was significantly related to AX metastases (Leatherm et
al., 1984; Fenlon et al., 1987), although other reports have
found no significant relationship between them (Fukutomi et
al., 1989; Galea et al., 1991). Moreover, using flow cytometry
and fresh breast cancer tissues, Alam et al. (1990) found a
correlation between HPA staining and nodal involvement
(P<0.001). This was confirmed in this study by the finding
that the majority of the HPA+ tumours were associated
with the presence of AX metastases. By multivariate analysis,
there appears to be a significant relationship between HPA
staining and AX metastases since the prognostic significance
of HPA staining was lost when nodal status was introduced
into the model. This confounding effect between both prog-
nostic factors has been found by Brooks and Leathem (1991)
but not by Fukutomi et al. (1989) who found that HPA
binding is a more informative prognostic factor for overall
survival than lymph node involvement. Although the
incidence of PHA staining (48%) in this study is similar to
that of Fukutomi et al. (1989) but not in agreement with the
80% incidence reported by Brooks et al. (1991), the
difference is less likely to be due to the type of staining
method or source of lectin than to the overall sensitivity of
the method. This may also have some general bearing on the
significance of HPA staining.
On the other hand, the function of the c-erbB-2 protein in
normal growth and differentiation of tumour cells remains
unclear. Its 50% amino acid sequence homology to EGFR
(Yamamoto et al., 1986) suggests that the c-erbB-2 receptor
may behave similarly to EGFR and be a potent growth
stimulator. Several studies (Tandon et al., 1989; Wright et al.,
1989; McCann et al., 1991) have reported that c-erbB-2 may
be a potential predictor for the course of the disease in breast
carcinoma patients. Amplification and overexpression of this
gene occurs more often in AX-positive patients (Thor et al.,
1989; Borg et al., 1991) as well as in tumours characterised
by high grade (Paik et al., 1990; Paterson et al., 1991), large
size (Borg et al., 1991) or absence of oestrogen and pro-
gesterone receptors (Thor et al., 1989; Borg et al., 1991;
Lovekin et al., 1991). In our previous study (Noguchi et al.,
1992), c-erbB-2 oncoprotein overexpression was significantly
associated with clinical stage and AX metastases.
In the present study, both HPA staining and c-erbB-2
overexpression were found to be strongly associated with theHPA AND c-erbB-2 IN BREAST CANCER 625
presence of AX metastases. Moreover, we found that the
c-erbB-2 status was predictive of a worse disease outcome
and a higher recurrence rate in both the HPA+ and HPA-
groups; however, of most interest is our finding that the
HPA+/c-erbB2+ patients had the worst prognosis when
compared with the other subgroups. Such a combined effect
has been reported for c-erbB2+ and EGFR-positive patients
(Wright et al., 1989). Thus, among patients regarded as
having a more favourable prognosis (HPA- group), c-erbB-
2 staining identified those who might benefit from more
aggressive therapy at an early stage. When HPA was assessed
against c-erbB-2, a strong association has been found
(P<O.O1) contrary to Galea et al. (1991) who found no
relation between HPA binding and all prognostic factors
tested (including c-erbB-2 status) except NCRC-11 (anti-
polymorphic epithelial mucin antibody). A possible explana-
tion for discrepancy may lie in differences in the staining
method and source of HPA; Galea et al. (1991) used a direct
peroxidase conjugated Helix pomatia method. In the future, a
study of the relationship between HPA staining and the
S-phase fraction will be required to determine whether HPA
staining is correlated with the proliferative ability of a
tumour. Since tumours with high proliferative activity may
have good responses to therapy (Bonnadonna et al., 1986),
HPA staining may assist in determining treatment strategies
for particular groups of patients.
In conclusion, we have shown that HPA staining is a
significant predictor for poorer disease-free and overall sur-
vival in primary breast carcinoma patients, although it was
not significant by multivariate analysis. However, one should
consider not only the status of HPA staining, but also the
status of the c-erbB-2 oncoprotein to discriminate more
precisely sub-populations with a high recurrence risk and
short survival who might benefit from more aggressive
therapy. This combination would provide a valuable prog-
nostic information for breast cancer patients in whom axil-
lary lymph node dissection has not been performed.
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